MGMT function determines the differential response of ATR inhibitors with DNA-damaging agents in glioma stem cells for GBM therapy.

Vincent W S LeongSabbir KhanPratibha SharmaShaofang WuRiya R ThomasXiaolong LiSanjay K SinghFrederick F LangAlfred W K YungDimpy Koul

Published in: Neuro-oncology advances (2023)

This research provides a rationale for selectively targeting MGMT-methylated cells using ATRis and TMZ combination. Overall, we believe that MGMT methylation status in GBM could serve as a robust biomarker for patient selection for ATRi combined with TMZ.

Keyphrases

stem cells
induced apoptosis
cell cycle arrest
case report
circulating tumor
cell free
dna methylation
clinical trial
cell therapy
genome wide
single molecule
endoplasmic reticulum stress
gene expression
dna damage response
oxidative stress
dna damage
nucleic acid
replacement therapy